Critical Outcome Technologies Inc. (COTI) is a biotechnology company focused on applying its computer-based technology, CHEMSAS, to identify, profile, optimize and select potential new drug candidates at the discovery stage of preclinical drug development. COTI is concentrated on developing drug candidates for the treatment of various cancers, human immunodeficiency virus (HIV), Alzheimer�s disease and multiple sclerosis. Cancer types specifically targeted include small cell lung cancer, adult myelogenous leukemia (AML), ovarian, endometrial, pancreatic, brain, breast and colorectal cancer. COTI 2 is a advanced compound in COTI�s drug development pipeline. COTI-2 is a novel small molecule that acts by inhibiting Akt/PKB (Protein kinase B) phosphorylation that leads to caspase-9 activation in cancer cells resulting in tumor cell death. In February 2012, the Company announced the development of 8 oral formulation candidates for COTI2 as potential Phase 1 oral formulations.